Manila Times Business
Bonito Biosciences and DaltonTx Announce AI-Driven Collaboration to Advance Precision Delivery for Oligotherapeutics
Collaboration combines Bonito’s proprietary functional delivery data engine and ligand discovery platform with DaltonTx’s adaptive AI technology to accelerate precision oligotherapeutic delivery, beginning in the CNS WALTHAM, Mass. and LONDON, May 27, 2026 (GLOBE NEWSWIRE) -- Bonito Biosciences ("Bonito”), a biotechnology company building the data foundation for programmable oligotherapeutic delivery, and”) DaltonTx, the intelligence backbone for modern drug discovery: connecting AI, human exper
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
1h ago
Ghana's 'anti-LGBTQ' law triggers both praise and outrage
2h ago
WHO chief visits epicentre of Ebola outbreak in DR Congo
2h ago
Vapofil Reviews [URGENT REPORT 2026] The Shocking VapoFil Male Enhancement Supplement Trend Everyone Is Talking About
2h ago